

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/N452B263687EN.html>

Date: September 2018

Pages: 53

Price: US\$ 3,500.00 (Single User License)

ID: N452B263687EN

Abstracts

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Nociceptin Receptor - Pipeline Review, H2 2018'; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre%li%and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.

The report 'Nociceptin Receptor - Pipeline Review, H2 2018' outlays comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 6 and 1 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones and Immunology which include indications Pain, Substance (Drug) Abuse, Neuropathic Pain (Neuralgia), Dyskinesia, Nociceptive Pain, Bladder Pain, Cancer Pain, Diabetic Neuropathic Pain, Drug Addiction, Hypersensitivity, Inflammatory Pain, Low Back Pain, Major Depressive Disorder, Osteoarthritis Pain, Overactive Bladder, Parkinson's Disease and Post-Traumatic Stress Disorder (PTSD).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)

The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects

The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Overview

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development

Blackthorn Therapeutics Inc

Grunenthal GmbH

Recordati SpA

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles

AT-076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-127 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTRX-246040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cebranopadol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRT-6010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OREX-1038 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Agonize ORL1 for Acute Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REC-0438 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Products

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Product Development Milestones

Featured News & Press Releases

Aug 29, 2018: Scientists take big step toward finding non-addictive pain killer

Dec 07, 2017: BlackThorn Therapeutics Presents Preclinical and Clinical Data from Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting

Jul 24, 2017: BlackThorn Therapeutics Enrolls First Patient in Phase 2a Study of Lead Compound, BTRX-246040, in Major Depressive Disorder

Jul 10, 2017: Orexigen Announces Presentation of Preclinical Data for OREX-1038 at the International Narcotics Research Conference

Jan 05, 2017: Orexigen Therapeutics Provides Update on OREX-1038 at 35th Annual J.P. Morgan Healthcare Conference

Sep 30, 2016: Grunenthal's cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain

Aug 09, 2016: NIH Grant Will Fund Development of Small Molecules for Post-Traumatic Stress Disorder

May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile

Feb 29, 2016: Cebranopadol Top-Line Data from Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Blackthorn Therapeutics Inc, H2 2018
Pipeline by Grunenthal GmbH, H2 2018
Pipeline by Recordati SpA, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Blackthorn Therapeutics Inc
Grunenthal GmbH
Recordati SpA

I would like to order

Product name: Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/N452B263687EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N452B263687EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

